Comment on Genuth. Should Sulfonylureas Remain an Acceptable First-Line Add-on to Metformin Therapy in Patients With Type 2 Diabetes? No, It’s Time to Move On! Diabetes Care 2015;38:170–175
Abstract
Genuth (1) discusses in a Counterpoint article several arguments against the use of sulfonylureas (SUs) as an add-on therapy to metformin. We understand that in this format he makes arguments against the use of SUs; however, we could not appreciate his oversimplification by ignoring within-class differences. Specifically, the safety of gliclazide is not recognized.
In the 2013 Dutch type 2 diabetes guidelines from the …
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.